<DOC>
	<DOCNO>NCT00047099</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give surgery may kill remain tumor cell follow surgery . It yet know combination chemotherapy regimen effective treat breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two different combination chemotherapy regimens treat woman primary breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time progression woman primary breast cancer treat fluorouracil , epirubicin , cyclophosphamide v docetaxel , epirubicin , cyclophosphamide . - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord metastatic axillary lymph node involvement ( 4-9 v 10 ) , hormone receptor status ( estrogen and/or progesterone ) primary tumor ( negative v positive ) , time adjuvant radiotherapy ( intermittently completion 50 % chemotherapy v completion chemotherapy ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fluorouracil IV 10-15 minute epirubicin IV 15 minute day 1 8 oral cyclophosphamide day 1-14 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive epirubicin IV 15 minute cyclophosphamide IV 1 hour day 1 , 21 , 42 , 63 docetaxel IV 1 hour day 84 , 105 , 126 , 147 absence disease progression unacceptable toxicity . Within 21 day completion chemotherapy , patient undergo adjuvant radiotherapy 5 day week 5.5 week . Alternatively , patient may undergo radiotherapy intermittently completion 50 % chemotherapy . Upon completion chemotherapy , patient positive hormone receptor status ( estrogen and/or progesterone ) receive oral tamoxifen daily 5 year . Additionally , patient positive hormone receptor status age 40 receive goserelin subcutaneously every 4 week 2 year . Quality life assess baseline , prior course chemotherapy , 4 week completion chemotherapy , 6 week completion radiotherapy , 6 month completion chemotherapy . Patients follow every 3 month 3 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 446 patient ( 223 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary epithelial invasive carcinoma breast T14 , N12 , M0 Must 4 metastatic axillary lymph node Complete resection primary tumor within past 5 week Free invasive carcinoma least 10 lymph node remove No inflammatory breast cancer No distant metastases chest xray , liver ultrasound , whole body bone scan Hormone receptor status : Estrogen and/or progesterone receptor status know PATIENT CHARACTERISTICS : Age 18 70 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy At least 32 week Hematopoietic WBC least 3,000/mm3 Platelet count least 100,000 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT/SGPT great 1.5 time ULN Alkaline phosphatase great 1.5 time ULN Albumin great 1.5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular No cardiomyopathy impair ventricular function No New York Heart Association class III IV heart disease No cardiac arrhythmia influence LVEF require medication No myocardial infarction within past 6 month No angina pectoris within past 6 month No uncontrolled arterial hypertension Other No primary malignancy except carcinoma situ cervix adequately treat basal cell skin cancer No know hypersensitivity docetaxel , epirubicin , fluorouracil , cyclophosphamide , study medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic antineoplastic therapy No concurrent cytotoxic antineoplastic therapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Other At least 3 week since prior investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>